[Human fibrinolysin: the new thrombolytic agent]. 1962

J ARAMENDI LIZCANO

UI MeSH Term Description Entries
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J ARAMENDI LIZCANO
September 1959, Produits pharmaceutiques,
J ARAMENDI LIZCANO
January 1961, Archives of surgery (Chicago, Ill. : 1960),
J ARAMENDI LIZCANO
May 1987, Clinical pharmacy,
J ARAMENDI LIZCANO
June 2016, Nihon rinsho. Japanese journal of clinical medicine,
J ARAMENDI LIZCANO
January 1981, Terapevticheskii arkhiv,
J ARAMENDI LIZCANO
January 1993, Ukrainskii biokhimicheskii zhurnal (1978),
J ARAMENDI LIZCANO
February 1953, Clinical science,
J ARAMENDI LIZCANO
August 1995, Cardiology clinics,
J ARAMENDI LIZCANO
January 1977, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!